Creative Medical Reports Statistically Significant ADAPT Trial Data and 93% Ultrasome Pilot Success
CELZ•Creative Medical secured WHO approval for Olastrocel and reported statistically significant 180-day ADAPT trial improvements in pain and disability with no serious safety events. Its Ultrasome pilot achieved 93% patient mobility and pain-relief success and its biodefense program is over 85% enrolled in a 1,000-veteran burn pit registry.
1. Olastrocel ADAPT Trial Progress
Creative Medical received WHO approval for the International Non-Proprietary Name 'Olastrocel' and disclosed positive interim blinded 180-day ADAPT trial results showing statistically significant reductions in disability and pain with no serious adverse or treatment-related safety signals. The FDA has cleared an expansion cohort for patients using under 90 mg daily morphine equivalents, which is now over 85% enrolled and monitored via an AI-enabled pain-medication tracking system.
2. Ultrasome Pilot Breakthrough
In April, the company’s cell-free Osteoarthritis therapy Ultrasome hit its primary endpoint in a pilot knee study, with 93% of participants reporting clinically meaningful improvements in mobility and pain relief. No serious adverse events were observed, positioning Ultrasome as a scalable regenerative candidate for the high-volume osteoarthritis market.
3. Biodefense Platform Advancement
Project PHOENIX’s burn pit registry obtained national approval and has enrolled over 85% of its targeted 1,000 U.S. veterans, leveraging a mobile-app registry and AI-driven data ingestion. This effort feeds into the CELZ-Biodefense Toxic Exposure Atlas, integrating multi-omics and clinical data to identify molecular signatures and potential regenerative countermeasures.
4. Capital Allocation and Next Steps
Creative Medical maintains a lean structure focused on non-dilutive funding and partnerships, aligning future financing with value-creating milestones. Near-term priorities include completing ADAPT cohort follow-up, advancing Phase 3 planning for chronic lower back pain, initiating controlled Ultrasome studies, and modeling AI-derived insights for the biodefense platform.
